Telix Pharmaceuticals Limited (NASDAQ:TLX) shares are up during Tuesday’s premarket session following the announcement that Part 1 of the ProstACT Global Phase 3 study achieved its primary objectives.
The study demonstrated an acceptable safety and tolerability profile for TLX591-Tx, a therapeutic candidate, adding momentum to the stock as broader markets experienced positive movement.
Pivotal Data
TLX591-Tx (lutetium-177 rosopatamab tetraxetan) is an investigational PSMA-targeted radio antibody-drug conjugate (rADC) for metastatic castration-resistant prostate cancer (mCRPC).
The ProstACT Global Phase 3 study confirmed the safety profile, biodistribution, and dosimetry of TLX591-Tx administered in two doses, 14 days apart, in combination with standard therapies.
The study included 36 patients with metastatic castration-resistant prostate cancer, reinforcing the potential for TLX591-Tx in combination with contemporary standard of care to become a first-line treatment option.
In addition, the company plans to present Part 1 data to the U.S. Food and Drug Administration (FDA) to seek an Investigational New Drug amendment for progressing to Part 2 of the study.
This expansion aims for an overall target enrollment of approximately 490 patients.
Telix Hits Fiscal 2025 Revenue Target
Australia-based Telix Pharmaceuticals reported fiscal 2025 revenue of approximately $804 million, aligning with its upgraded guidance of $800-$820 million.
The company also noted a significant 46% year-over-year increase in the fourth quarter revenue, totaling around $208 million.
Analyst View
William Blair on Tuesday wrote, “In the absence of efficacy metrics, we are encouraged by the long tumor residence time of TLX591, which remained in tumors for a week following dosing and was detectable through 15 days.”
“This dynamic stands in contrast with the blood radioactivity, which experienced a decline over time with tumor lesion radioactivity surpassing the blood pool 4 days after dosing,” analyst Andy Hsieh wrote.
Technical Analysis
The stock is currently trading 14.9% above its 20-day simple moving average (SMA) and 5.8% below its 100-day SMA, suggesting some short-term strength but longer-term challenges.
Shares have decreased 58.04% over the past 12 months and are currently positioned closer to their 52-week lows than highs.
The RSI is at 54.50, which is considered neutral territory, indicating no immediate overbought or oversold conditions. Meanwhile, MACD shows a value of -0.0267, with the signal line at -0.1252, suggesting a bullish signal as MACD is above the signal line.
The combination of neutral RSI and bullish MACD suggests mixed momentum, indicating that while the stock is not overbought, there is potential for upward movement.
- Key Resistance: $10.50
- Key Support: $7.00
Analyst Consensus & Recent Actions: The stock carries a Buy Rating with an average price target of $21.63. Recent analyst moves include:
- Citigroup: Buy (Raises Target to $22.50) (Feb. 24)
- HC Wainwright & Co.: Buy (Maintains Target to $20.00) (Jan. 21)
Benzinga Edge Rankings
Below is the Benzinga Edge scorecard for Telix Pharmaceuticals, highlighting its strengths and weaknesses compared to the broader market:
- Value Rank: 6.22 — The stock is trading at a premium relative to its peers.
- Momentum Rank: 4.9 — The stock is underperforming the broader market.
The Verdict: Telix Pharmaceuticals’ Benzinga Edge signal reveals a mixed outlook. While the Value Rank indicates a premium valuation, the low Momentum Rank suggests that the stock is currently underperforming compared to the market.
TLX Price Action: Telix Pharmaceuticals shares were up 1.20% at $7.58 during premarket trading on Tuesday, according to Benzinga Pro data.
Photo via Shutterstock
Recent Comments